drugset

drugset / Trial / NCT04227470

A Study of HBM9161 in NMOSD Patients

NCT04227470 ↗

Phase 1 Completed 9 enrolled Harbour BioMed (Guangzhou) Co. Ltd.

NaSequentialOpen-labelTreatment

Summary

Primary Objectives:To investigate the safety and tolerability of HBM 9161 in patients with attack of NMOSD in China

Timeline

Start: 2020-03-31
Primary completion: 2021-12-03
Completion: 2021-12-24

Publications

Wang J, Cai G, Xia S, Qin J, Liu B. Research hotspots and emerging topics in neuromyelitis optica spectrum disorder treatment: Insights from a bibliometric analysis. Medicine (Baltimore). 2025 Jun 6;104(23):e42850. doi: 10.1097/MD.0000000000042850.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Batoclimab	Monoclonal antibody	340 mg	Subcutaneous
Subject	Batoclimab	Monoclonal antibody	680 mg	Subcutaneous

Indications